Clinical Trials | October 09, 2022
ICON selected by BARDA to conduct anthrax vaccine clinical trial
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Subscribe To Our Newsletter & Stay Updated
